Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 0.16
ZTS's Cash to Debt is ranked lower than
51% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.43 vs. ZTS: 0.16 )
ZTS' s 10-Year Cash to Debt Range
Min: 0.1   Max: No Debt
Current: 0.16

Equity to Asset 0.21
ZTS's Equity to Asset is ranked lower than
51% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. ZTS: 0.21 )
ZTS' s 10-Year Equity to Asset Range
Min: 0.12   Max: 0.69
Current: 0.21

0.12
0.69
Interest Coverage 7.03
ZTS's Interest Coverage is ranked higher than
55% of the 546 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 101.95 vs. ZTS: 7.03 )
ZTS' s 10-Year Interest Coverage Range
Min: 2.3   Max: 13.28
Current: 7.03

2.3
13.28
F-Score: 6
Z-Score: 4.33
M-Score: -2.49
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 19.56
ZTS's Operating margin (%) is ranked higher than
90% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.41 vs. ZTS: 19.56 )
ZTS' s 10-Year Operating margin (%) Range
Min: -4.53   Max: 17.41
Current: 19.56

-4.53
17.41
Net-margin (%) 11.91
ZTS's Net-margin (%) is ranked higher than
84% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.06 vs. ZTS: 11.91 )
ZTS' s 10-Year Net-margin (%) Range
Min: -3.62   Max: 11.05
Current: 11.91

-3.62
11.05
ROE (%) 51.24
ZTS's ROE (%) is ranked higher than
99% of the 876 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. ZTS: 51.24 )
ZTS' s 10-Year ROE (%) Range
Min: 11.26   Max: 20.3
Current: 51.24

11.26
20.3
ROA (%) 8.71
ZTS's ROA (%) is ranked higher than
88% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.17 vs. ZTS: 8.71 )
ZTS' s 10-Year ROA (%) Range
Min: 7.28   Max: 8.58
Current: 8.71

7.28
8.58
ROC (Joel Greenblatt) (%) 32.33
ZTS's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.06 vs. ZTS: 32.33 )
ZTS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 25.88   Max: 36.32
Current: 32.33

25.88
36.32
» ZTS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ZTS Guru Trades in Q4 2013

Paul Tudor Jones 6,200 sh (New)
Jim Simons 779,000 sh (New)
Lee Ainslie 7,635,025 sh (+2021.15%)
George Soros 2,495,329 sh (+54.13%)
Mario Gabelli 282,960 sh (+15.61%)
Jean-Marie Eveillard 6,647,674 sh (+13.77%)
John Keeley 81,582 sh (+0.08%)
George Soros 186,000 sh (unchged)
Ruane Cunniff 173,973 sh (unchged)
Vanguard Health Care Fund 8,412,017 sh (unchged)
Robert Olstein 160,000 sh (unchged)
Chuck Royce Sold Out
Louis Moore Bacon Sold Out
Pioneer Investments 1,924,824 sh (-0.02%)
RS Investment Management 2,234,184 sh (-1.42%)
Steven Cohen 4,749,899 sh (-26.65%)
» More
Q1 2014

ZTS Guru Trades in Q1 2014

Joel Greenblatt 42,374 sh (New)
Paul Tudor Jones 15,774 sh (+154.42%)
George Soros 4,205,043 sh (+68.52%)
Vanguard Health Care Fund 10,421,717 sh (+23.89%)
RS Investment Management 2,687,539 sh (+20.29%)
Robert Olstein 178,000 sh (+11.25%)
Lee Ainslie Sold Out
Ruane Cunniff 173,553 sh (-0.24%)
Pioneer Investments 1,913,056 sh (-0.61%)
John Keeley 79,108 sh (-3.03%)
Mario Gabelli 260,552 sh (-7.92%)
Jean-Marie Eveillard 3,763,386 sh (-43.39%)
Jim Simons 163,303 sh (-79.04%)
Steven Cohen 683,462 sh (-85.61%)
» More
Q2 2014

ZTS Guru Trades in Q2 2014

Pioneer Investments 2,254,815 sh (+17.86%)
George Soros 4,386,635 sh (+4.32%)
Vanguard Health Care Fund 10,798,417 sh (+3.61%)
Ruane Cunniff 173,562 sh (+0.01%)
Robert Olstein 178,000 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
RS Investment Management 2,548,819 sh (-5.16%)
John Keeley 74,504 sh (-5.82%)
Mario Gabelli 242,980 sh (-6.74%)
Joel Greenblatt 33,034 sh (-22.04%)
Jean-Marie Eveillard 2,177,060 sh (-42.15%)
» More
Q3 2014

ZTS Guru Trades in Q3 2014

Bill Ackman 5,536,862 sh (New)
John Keeley 79,504 sh (+6.71%)
Vanguard Health Care Fund 10,798,417 sh (unchged)
Robert Olstein 178,000 sh (unchged)
Joel Greenblatt Sold Out
Jean-Marie Eveillard 2,174,162 sh (-0.13%)
Ruane Cunniff 173,322 sh (-0.14%)
Pioneer Investments 2,203,980 sh (-2.25%)
RS Investment Management 2,491,074 sh (-2.27%)
George Soros 4,031,735 sh (-8.09%)
Mario Gabelli 217,980 sh (-10.29%)
» More
» Details

Insider Trades

Latest Guru Trades with ZTS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Bill Ackman 2014-09-30 New Buy1.5%$31.79 - $37.2 $ 43.326%5536862
Joel Greenblatt 2014-09-30 Sold Out 0.01%$31.79 - $37.2 $ 43.326%0
Jean-Marie Eveillard 2014-06-30 Reduce -42.15%0.12%$28.4 - $32.89 $ 43.341%2177060
Joel Greenblatt 2014-06-30 Reduce -22.04%$28.4 - $32.89 $ 43.341%33034
Lee Ainslie 2014-03-31 Sold Out 3.2%$29.01 - $32.69 $ 43.341%0
George Soros 2014-03-31 Add 68.52%0.49%$29.01 - $32.69 $ 43.341%4205043
Jean-Marie Eveillard 2014-03-31 Reduce -43.39%0.26%$29.01 - $32.69 $ 43.341%3763386
Vanguard Health Care Fund 2014-03-31 Add 23.89%0.16%$29.01 - $32.69 $ 43.341%10421717
Joel Greenblatt 2014-03-31 New Buy0.02%$29.01 - $32.69 $ 43.341%42374
Lee Ainslie 2013-12-31 Add 2021.15%3.05%$31.04 - $33.22 $ 43.336%7635025
George Soros 2013-12-31 Add 54.13%0.24%$31.04 - $33.22 $ 43.336%2495329
Jean-Marie Eveillard 2013-09-30 Add 1447.21%0.5%$29.15 - $32.72 $ 43.341%5842948
George Soros 2013-09-30 Reduce -32.68%0.26%$29.15 - $32.72 $ 43.341%1619011
Lee Ainslie 2013-09-30 New Buy0.15%$29.15 - $32.72 $ 43.341%359948
Mario Gabelli 2013-09-30 Add 350.26%0.04%$29.15 - $32.72 $ 43.341%244760
Joel Greenblatt 2013-09-30 Sold Out 0.04%$29.15 - $32.72 $ 43.341%0
Ruane Cunniff 2013-09-30 Add 767.96%0.03%$29.15 - $32.72 $ 43.341%173973
John Keeley 2013-09-30 Add 95.24%0.02%$29.15 - $32.72 $ 43.341%81519
Vanguard Health Care Fund 2013-06-30 Add 1167.44%0.88%$30.19 - $34.26 $ 43.334%8412017
George Soros 2013-06-30 Add 262.41%0.59%$30.19 - $34.26 $ 43.334%2404811
Robert Olstein 2013-06-30 Add 57.14%0.26%$30.19 - $34.26 $ 43.334%143000
Joel Greenblatt 2013-06-30 New Buy0.04%$30.19 - $34.26 $ 43.334%30457
Jean-Marie Eveillard 2013-06-30 Add 655.29%0.03%$30.19 - $34.26 $ 43.334%377645
John Keeley 2013-06-30 New Buy0.03%$30.19 - $34.26 $ 43.334%41753
Mario Gabelli 2013-06-30 New Buy0.01%$30.19 - $34.26 $ 43.334%54360
Robert Olstein 2013-03-31 New Buy0.53%$31.01 - $34.64 $ 43.331%91000
George Soros 2013-03-31 New Buy0.26%$31.01 - $34.64 $ 43.331%663568
Vanguard Health Care Fund 2013-03-31 New Buy0.09%$31.01 - $34.64 $ 43.331%663700
Jean-Marie Eveillard 2013-03-31 New Buy0.01%$31.01 - $34.64 $ 43.331%50000
Ruane Cunniff 2013-03-31 New Buy$31.01 - $34.64 $ 43.331%20000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 39.40
ZTS's P/E(ttm) is ranked higher than
78% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.40 vs. ZTS: 39.40 )
ZTS' s 10-Year P/E(ttm) Range
Min: 27.31   Max: 42.59
Current: 39.4

27.31
42.59
Forward P/E 22.78
ZTS's Forward P/E is ranked higher than
85% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 56.18 vs. ZTS: 22.78 )
N/A
PE(NRI) 39.40
ZTS's PE(NRI) is ranked higher than
78% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.90 vs. ZTS: 39.40 )
ZTS' s 10-Year PE(NRI) Range
Min: 27.31   Max: 42.59
Current: 39.4

27.31
42.59
P/B 16.20
ZTS's P/B is ranked higher than
52% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. ZTS: 16.20 )
ZTS' s 10-Year P/B Range
Min: 12.65   Max: 24.37
Current: 16.2

12.65
24.37
P/S 4.60
ZTS's P/S is ranked higher than
69% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.02 vs. ZTS: 4.60 )
ZTS' s 10-Year P/S Range
Min: 3.11   Max: 4.77
Current: 4.6

3.11
4.77
PFCF 62.20
ZTS's PFCF is ranked higher than
84% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. ZTS: 62.20 )
ZTS' s 10-Year PFCF Range
Min: 25.57   Max: 90.29
Current: 62.2

25.57
90.29
POCF 41.21
ZTS's POCF is ranked higher than
75% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 38.72 vs. ZTS: 41.21 )
ZTS' s 10-Year POCF Range
Min: 21.59   Max: 41.99
Current: 41.21

21.59
41.99
EV-to-EBIT 27.23
ZTS's EV-to-EBIT is ranked higher than
81% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.35 vs. ZTS: 27.23 )
ZTS' s 10-Year EV-to-EBIT Range
Min: 20.9   Max: 28.1
Current: 27.23

20.9
28.1
PEG 1.44
ZTS's PEG is ranked higher than
93% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. ZTS: 1.44 )
ZTS' s 10-Year PEG Range
Min: 0   Max: 9973.9
Current: 1.44

0
9973.9
Current Ratio 3.36
ZTS's Current Ratio is ranked higher than
78% of the 881 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. ZTS: 3.36 )
ZTS' s 10-Year Current Ratio Range
Min: 2.29   Max: 3.47
Current: 3.36

2.29
3.47
Quick Ratio 1.97
ZTS's Quick Ratio is ranked higher than
73% of the 881 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. ZTS: 1.97 )
ZTS' s 10-Year Quick Ratio Range
Min: 1.35   Max: 1.97
Current: 1.97

1.35
1.97
Days Inventory 285.74
ZTS's Days Inventory is ranked higher than
58% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 149.40 vs. ZTS: 285.74 )
ZTS' s 10-Year Days Inventory Range
Min: 117.43   Max: 288.46
Current: 285.74

117.43
288.46
Days Sales Outstanding 81.76
ZTS's Days Sales Outstanding is ranked higher than
74% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 86.21 vs. ZTS: 81.76 )
ZTS' s 10-Year Days Sales Outstanding Range
Min: 75.1   Max: 91.07
Current: 81.76

75.1
91.07

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.69
ZTS's Dividend Yield is ranked lower than
75% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.35 vs. ZTS: 0.69 )
ZTS' s 10-Year Dividend Yield Range
Min: 0.21   Max: 0.94
Current: 0.69

0.21
0.94
Dividend Payout 0.25
ZTS's Dividend Payout is ranked higher than
86% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.43 vs. ZTS: 0.25 )
ZTS' s 10-Year Dividend Payout Range
Min: 0.22   Max: 0.31
Current: 0.25

0.22
0.31
Yield on cost (5-Year) 0.70
ZTS's Yield on cost (5-Year) is ranked lower than
75% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.46 vs. ZTS: 0.70 )
ZTS' s 10-Year Yield on cost (5-Year) Range
Min: 0.21   Max: 0.94
Current: 0.7

0.21
0.94

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.30
ZTS's Price/Median PS Value is ranked higher than
70% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. ZTS: 1.30 )
ZTS' s 10-Year Price/Median PS Value Range
Min: 0.89   Max: 1.1
Current: 1.3

0.89
1.1
Earnings Yield (Greenblatt) 3.70
ZTS's Earnings Yield (Greenblatt) is ranked higher than
80% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. ZTS: 3.70 )
ZTS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.6   Max: 4.8
Current: 3.7

3.6
4.8

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:ZOE.Germany,
Zoetis Inc was incorporated in Delaware in July 2012. It is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. It markets products across four regions: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific; eight core species: the livestock species of cattle, swine, poultry, sheep and fish, and the companion animal species of dogs, cats and horses; and five product categories: anti-infectives - products that prevent, kill or slow the growth of bacteria, fungi or protozoa; vaccines - biological preparations that help prevent diseases of the respiratory, gastrointestinal and reproductive tracts or induce a specific immune response; parasiticides - products that prevent or eliminate external and internal parasites such as fleas, ticks and worms; medicated feed additives; and other pharmaceutical products - pain and sedation, oncology, antiemetic, allergy and dermatology; and reproductive products. The Company organizes and operates its business in four segments: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific. The Company sells its livestock products directly to a diverse set of livestock producers, including beef and dairy farmers as well as pork, poultry and aquaculture operations, and to veterinarians, third-party veterinary distributors and retail outlets that typically then sell the products to livestock producers. It primarily sells its companion animal products to veterinarians or to third-party veterinary distributors that typically then sell its products to veterinarians, and in each case veterinarians then typically sell its products to pet owners. Its primary competitors include animal health medicines and vaccines companies such as Merck Animal Health, the animal health division of Merck & Co., Inc. (formerly known as Intervet/Schering-Plough); Merial, the animal health division of Sanofi S.A.; Elanco, the animal health division of Eli Lilly and Company; Bayer Animal Health, the animal health division of Bayer AG; Novartis Animal Health, the animal health division of Novartis AG; and Boehringer Ingelheim Animal Health, the animal health division of Boehringer Ingelheim GmbH. In addition, it competes with hundreds of other animal health product producers throughout the world.
» More Articles for ZTS

Headlines

Articles On GuruFocus.com
Feeling Good With This Med Company Jan 20 2015 
2015 - First Half Jan 01 2015 
Zoetis in a Growing Global Animal Health Industry Dec 03 2014 
Ackman’s Pershing Group Buys Stake in Zoetis Nov 13 2014 
Activist Bill Ackman Buys Big Stake In Animal Healthcare Company Zoetis Nov 12 2014 
Zoetis Will Benefit from Industry Trends Oct 07 2014 
Guru Stocks at 52-Week Lows: HMC, NMR, SDRL, ZTS, BBBY Apr 21 2014 
Morning Coffee: Widely Held Guru Stocks Near 52-Week Lows Apr 10 2014 
Morning Coffee: Guru Stocks Near 52-Week Lows Apr 03 2014 
Guru Stocks at 52-Week Lows: CEO, BCS, HMC, ED, ZTS Apr 01 2014 

More From Other Websites
Bill Ackman on Receiving End of Hedge Fund Selling Jan 28 2015
Top activist plays for 2015 Jan 21 2015
BUZZ-Indivior: Citi tips spinoff to outperform parent Jan 05 2015
3 hedge fund predictions for 2015 Dec 31 2014
Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2014 Financial Results Dec 31 2014
Zoetis Boosts Dividend After Ackman Raises Stake Dec 17 2014
Zoetis raises quarterly dividend 15% Dec 17 2014
ZOETIS INC. Files SEC form 8-K, Regulation FD Disclosure Dec 17 2014
Zoetis Declares First Quarter 2015 Dividend; Board Approves 15% Payment Increase Dec 17 2014
Zoetis to Participate in the 33rd Annual J.P. Morgan Healthcare Conference Dec 17 2014
Livestock products lead Zoetis’ 3Q14 revenue growth Dec 11 2014
Must-know trends that drive Zoetis’ growth Dec 10 2014
Zoetis: An attractive business model Dec 10 2014
Pershing Square takes 8.5% stake in Zoetis Dec 10 2014
Zoetis Inc. Spikes Briefly On Remarks From Sanofi CEO Dec 09 2014
Bayer Doesn’t Look Ready for Animal Magnetism Dec 05 2014
Zoetis in a Growing Global Animal Health Industry Dec 03 2014
Zoetis to Participate in the Bank of America Animal & Dental Health Summit Dec 02 2014
Jefferies Raises Zoetis Price Target, Says Consolidation Continues To Look Likely Nov 26 2014
Bayer explores possible sale of diabetes device unit -Bloomberg Nov 24 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK